GTB-3650 Tri-Specific Killer Engager (TriKE®)
HM2023-05: GTB-3650 (Anti-CD16/IL-15/Anti-CD33) Tri-Specific Killer Engager (TriKE®) for the Treatment of High Risk Myelodysplastic Syndromes (MDS) and Refractory/Relapsed Acute Myeloid Leukemia (AML)
Near Add Your Location
Sorting 1 by
Center of Excellence
University of Minnesota - Masonic Cancer Center
Minneapolis, MN
- Accepting patients
Showing 1-1 of 1
Real People. Real Support.
Need help connecting with this clinical trial? We're here to help!
Print a patient-friendly report to share with your patient.
We can help answer any questions and connect you (or your patient) with the study team.
Schedule a time that is convenient and we’ll call you to see how we can help you and your patient.